GlassScriptPhysician profile
Brian T Lovitt
NPI 1699110189
$3,690.31
in general payments reported to CMS, 2019-2025
25 companies · $45.98 in 2025
The $45.98 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $287 · 2021: $325 · 2022: $500 · 2023: $551 · 2024: $78.34 · 2025: $45.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,455.89 | 2019-2020 | |
| Astellas Pharma US INC | $412.39 | 2019-2023 | Veozah, Myrbetriq |
| Abbvie INC. | $387.98 | 2019-2023 | |
| Coopersurgical, INC. | $217.87 | 2019-2023 | Paragard T 380a |
| Pfizer INC. | $214.15 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.82 | 2019-2023 | |
| Organon LLC | $111.50 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $108.68 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $102.58 | 2022-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Omni Hysteroscope |
| Mayne Pharma Commercial LLC | $81.69 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $69.93 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $55.94 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $55.60 | 2019-2020 | |
| Medtronic, INC. | $42.44 | 2023-2024 | Truclear, Ligasure |
| Merck Sharp & Dohme LLC | $34.83 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $33.01 | 2023 | Twirla |
| Myovant Sciences INC. | $30.30 | 2022 | |
| Avion Pharmaceuticals | $29.40 | 2021-2022 | |
| Allergan, INC. | $24.99 | 2019 | |
| Biogen, INC. | $23.35 | 2024 | |
| Mylan Pharmaceuticals INC. | $18.79 | 2021 | |
| Shield Therapeutics INC | $17.14 | 2023 | Accrufer |
| Urovant Sciences INC | $13.91 | 2021 | |
| Amgen INC. | $12.72 | 2021 | |
| Novo Nordisk INC | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lovitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.